Simone Rizzetto @SimoneRizzetto88: "📊 PORTFOLIO UPDATE: Earnings Avalanche,..."

Italy

📊 PORTFOLIO UPDATE: Earnings Avalanche, FDA Breakthroughs, and AI Wars 🚀 One week since the last update and we entered the busiest earnings window of the quarter. Portfolio is stable. YTD +13.33%, MTD +0.93%. 📌 Pharma: Lipfendra Approval ➤ $MRK (Merck & Co.): FDA approved Lipfendra on July 16, the first-ever oral PCSK9 inhibitor for cholesterol. A first-of-its-kind pill replacing injectables. Sac-TMT plus Keytruda showed positive lung cancer results with a $25B peak sales opportunity. BofA and RBC Capital maintain Buy at $141-$142. My position up over 57%. 📌 Biotech: Catalysts and M&A ➤ Major M&A: Tempus AI announced acquisition of $PSNL (Personalis Inc) today for $1.5B at $16.25 per share, a 28% premium. Merck was reportedly competing as a suitor before Tempus prevailed. Deal integrates MRD cancer testing with Tempus AI platform, expected close early 2027. Tempus stock dropped ~9% on dilution concerns but the MRD market opportunity is $20B. $PSNL shares also dropped as the M&A price was underwhelming. Currently trading 20% below acquisition price, I decided to add more. Even if it takes a year for the acquisition to be completed, and there is a bit of risk involved in the transaction, this trade may yield additional 20% profit with little risk. ➤ $NTRA (Natera Inc): CMS finalized expanded Medicare coverage for MolDx Prospera transplant tests effective August 30. 📌 Healthcare Earnings ➤ $ISRG (Intuitive Surgical Inc): Revenue up 19% to $2.9B, EPS beat. But did NOT raise guidance. Reaffirmed only 13.5%-15.5% growth. Stock crashed 14% to $344.55, worst day in 4 years. FDA flagged stapler device safety issue. I still hold it as diversification and further potential expansion with AI+robotics for surgery. ➤ $CVS (CVS Health Corp): Complete opposite. FTC $13B settlement resolved all PBM litigation. Wells Fargo PT to $123, multiple firms followed upgrades. Hit 52-week high, up 74% year-over-year. Consensus Strong Buy. ➤ $UNH (UnitedHealth): Reported Q2 on July 16 and crushed it. Adjusted EPS $6.38 versus $4.85 consensus, operating earnings $8B up 55% YoY. Raised full-year guidance. Medical care ratio improved to 88.6%. Total revenue steady at $112B. Wall Street called it "impressive" with 20% more room to run. Stock up ~30% YTD, my position up over 41%. 🚀 Tech: AI Infrastructure and Earnings ➤ $META (Meta Platforms Inc): Launched "Meta Compute" cloud business to monetize AI infrastructure. $10B deal in talks with Anthropic. Iris chip entering production September. Stock up 15% in one week, best since early 2024. 91% analysts rate Buy, $810 target. ⏳ Ahead TSM already reported a blowout beat with 2nm shipping and $100B Arizona expansion. Multiple earning reports going to be released in the next 2-3 weeks. Fed meets July 28-29. The next weeks define H2 momentum. $SPX500 $NSDQ100

Not investment advice. The author may have financial interests in the mentioned instruments.